understand and respond appropriately. The project activities and methods will remain the same as those used in the previously approved collection.

Data are collected through anonymous, in-person interviews conducted with persons systematically selected from 25 Metropolitan Statistical Areas (MSAs) throughout the United States; these 25 MSAs were chosen based on having high AIDS prevalence. Persons at risk for HIV infection to be interviewed for NHBS include men who have sex with men (MSM), injecting drug users (IDUs), and heterosexuals at increased risk of HIV (HET). A brief screening interview will be used to determine eligibility for participation in the behavioral assessment. The data from the behavioral assessment will provide estimates of behavior related to the risk of HIV and other sexually transmitted diseases, prior testing for HIV, and use of HIV prevention services. All persons interviewed will also be offered an HIV test and will participate in a pre-test counseling session. No other federal agency systematically collects this type of information from persons at risk for HIV infection. These data have substantial impact on prevention program development and monitoring at the local, state, and national levels.

CDC estimates that NHBS will involve, per year in each of the 25 MSAs, eligibility screening for 50 to 200 persons and eligibility screening plus the survey with 500 eligible respondents, resulting in a total of 37,500 eligible survey respondents and 7,500 ineligible screened persons during a 3-year period. Data collection will rotate such that interviews will be conducted among one group per year: MSM in year 1, IDU in year 2, and HET in year 3. The type of data collected for each group will vary slightly due to different sampling methods and risk characteristics of the group.

This request is for a revision and an approval for an additional 3 years of data collection. Participation of respondents is voluntary and there is no cost to the respondents other than their time. The total estimated annualized burden hours are 9,931.

### ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Form name</th>
<th>Number of respondents</th>
<th>Responses per respondent</th>
<th>Average burden per response; (in hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year 1 (MSM):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persons Screened</td>
<td>Screener</td>
<td>17,500</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td>Eligible Participants</td>
<td>Survey</td>
<td>12,500</td>
<td>1</td>
<td>30/60</td>
</tr>
<tr>
<td>Year 2 (IDU):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persons Screened</td>
<td>Screener</td>
<td>13,750</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td>Eligible Participants</td>
<td>Survey</td>
<td>12,500</td>
<td>1</td>
<td>54/60</td>
</tr>
<tr>
<td>Peer Recruiters</td>
<td>Recruiter Debriefing</td>
<td>6,250</td>
<td>1</td>
<td>2/60</td>
</tr>
<tr>
<td>Year 3 (HET):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persons Screened</td>
<td>Screener</td>
<td>13,750</td>
<td>1</td>
<td>5/60</td>
</tr>
<tr>
<td>Eligible Participants</td>
<td>Survey</td>
<td>12,500</td>
<td>1</td>
<td>39/60</td>
</tr>
<tr>
<td>Peer Recruiters</td>
<td>Recruiter Debriefing</td>
<td>6,250</td>
<td>1</td>
<td>2/60</td>
</tr>
</tbody>
</table>

Petunia Gissendaner,  
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.  
[FR Doc. 2011–5092 Filed 3–4–11; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number NIOSH–226]


AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of public comment period.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) requests comments from the public on implementing the provisions of the James Zadroga 9/11 Health and Compensation Act of 2010 (Pub. L. 111–347). A copy of the Act is posted on the Internet at http://www.cdc.gov/niosh/docket in the NIOSH Docket number 226. The Federal government is developing an implementation plan, and comments from the public will assist in this process by gaining perspectives from interested parties on ways to meet the Act's requirements. The public is invited to submit written comments to the NIOSH Docket number 226. A public meeting on March 3, 2011, was previously announced in the Federal Register (76 FR 7862) on February 11, 2011 to accept oral comments from the public.

Public Comment Period: All comments must be received by April 29, 2011.

ADDRESSES: Written comments may be submitted to the NIOSH Docket Office, identified by Docket number NIOSH–226, by any of the following methods:

- Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS–C34, 4676 Columbia Parkway, Cincinnati, OH 45226.
- Facsimile: (513) 533–8285.
- E-mail: nioshdocket@cdc.gov.

All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio 45226.

A complete electronic docket containing a copy of the James Zadroga 9/11 Health and Compensation Act of 2010 (Pub. L. 111–347) and all comments submitted will be available on the NIOSH Web site at http://www.cdc.gov/niosh/docket. All comments received will be available for public inspection, including any personally identifiable or confidential business information that is included in a comment. Because comments will be made public, they should not include any sensitive personal information, such as a person’s social security number; date of birth; driver’s license number; state identification number or foreign country equivalent; passport number; financial account number; or credit or debit card number. Comments also should not include any sensitive health information, such as medical records or other individually identifiable health
information, or any non-public corporate or trade association information, such as trade secrets or other proprietary information.

FOR FURTHER INFORMATION CONTACT: Roy Fleming, Sc.D., CDC/NIOSH, 1600 Clifton Road, NE., MS–E20, Atlanta, Georgia 30333, Toll free 1–866–426–3673, e-mail: nioshdocket@cdc.gov.


John Howard,
Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2011–5111 Filed 3–4–11; 8:45 am]
BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Determine of the Benefits of Work and/or School Exclusion to Respiratory Illness in Decreasing Influenza Transmission, Funding Opportunity Number (FOA) CK11–007, Initial Review

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 8 a.m.–5 p.m., May 2, 2011 (Closed).

Place: Sheraton Gateway Hotel Atlanta Airport, 1900 Sullivan Road, Atlanta, Georgia 30337, Telephone: (770) 997–1100.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: [The meeting will include the initial review, discussion, and evaluation of applications received in response to “Determine of the Benefits of work and/or School Exclusion to Respiratory Illness in Decreasing Influenza Transmission”]

Contact Person for More Information: Dr. Amy Yang, Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E66, Atlanta, Georgia 30333, Telephone: (404) 498–2733.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 25, 2011.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–5102 Filed 3–4–11; 8:45 am]
BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Request for Information: Update of NIOSH Nanotechnology Strategic Plan for Research and Guidance

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of public comment period.

SUMMARY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) seeks comment on the types of hazard identification and risk management research that should be considered for updating the NIOSH 2009 nanotechnology strategic plan.

Public Comment Period: Comments must be received by April 15, 2011.

ADDRESS:

Written comments, identified by docket number NIOSH 134–A, may be submitted by any of the following ways:

• Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS–C–34, 4676 Columbia Parkway, Cincinnati, Ohio 45226.

• Facsimile: (513) 533–8285.

E-mail: nioshdocket@cdc.gov.

All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, 4676 Columbia Parkway, Room 109, Cincinnati, Ohio 45226. A complete electronic docket containing all comments submitted will be available thirty days after the public comment period on the NIOSH Web page at http://www.cdc.gov/niosh/docket, and comments will be available in writing by request. NIOSH includes all comments received without change in the docket, including any personal information provided. All electronic comments should be submitted as Microsoft Word. Please make reference to docket number NIOSH 134–A.

Background: Since 2004, the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) has pioneered research on the toxicological properties and characteristics of nanoparticles. This research has involved characterizing occupationally relevant nanoparticles for predicting whether these particles pose a risk of adverse health effects and for providing guidance on controlling workplace exposures. In September 2005, NIOSH developed a strategic plan to further guide the Institute in identifying and prioritizing nanotechnology research. In 2009 this strategic plan [http://www.cdc.gov/niosh/topics/nanotech/strat_plan.html] was updated based on knowledge gained from results of ongoing NIOSH research [see Progress Toward Safe Nanotechnology in the Workplace; A Report from the NIOSH Nanotechnology Research Center http://www.cdc.gov/niosh/docs/2007–123/] and from stakeholder input.

NIOSH would like to build on the accomplishments of ongoing research [see http://www.cdc.gov/niosh/docs/2010–104/] to develop strategic research goals and objectives through 2015. NIOSH has identified 10 critical research areas for nanotechnology research and communication. These 10 critical research areas are (1) toxicity and internal dose, (2) measurement methods, (3) exposure assessment, (4) epidemiology and surveillance, (5) risk assessment, (6) engineering controls and personal protective equipment (PPE), (7) fire and explosion safety, (8) recommendations and guidance, (9) communication and information, and (10) applications.

NIOSH is considering focusing the overarching strategic research goals for these critical areas on 5 key goals: (1) Provide guidance to protect workers, (2) alert workers, employers, governments, and the public about possible new hazards, (3) assess the hazards of nanomaterials and the risks to workers, (4) help workers by assessing and implementing exposure registries, and (5) assess the level of protection practiced in US workplaces.

NIOSH requests comment on how research in these 10 critical areas and the 5 overarching goals can be enhanced. Examples of requested information include, but are not limited to:

(1) The need for toxicity evaluation and/or workplace exposure characterization of engineered nanoparticles not currently being studied*.